

Africure Pharmaceuticals Ltd
(Incorporated in the Republic of Mauritius)
(Registration number: C145852 C1/GBL)
Having its registered address at
6th Floor, Tower A, 1 Cybercity, Ebene, Republic of Mauritius
("Africure" or "the Company")



ISSUE AND LISTING OF NEW SHARES

Shareholders of the Company are hereby advised that the Listing Executive Committee of the Stock Exchange of Mauritius Ltd ("SEM") has on 14 October 2024, approved the issue and listing of 2,260,000 additional ordinary shares of the Company (the "new shares") on the Official Market of the SEM, by way of consideration issue. The new shares will be issued to Avacare Global ("Avacare") at a price of USD 3.4348 per ordinary share, as settlement for the transfer of Avacare's remaining shareholding in various subsidiaries of Africure (Africure Pharmaceuticals Cote D'Ivoire, Africure Pharmaceuticals Manufacturing Ethiopia PLC and Zenufa Laboratories Limited) to the Company.

The date of issue and listing of the new shares will be communicated in due course. Following the issue of the new shares, Africure shall have a total of 11,677,500 ordinary shares in issue.

As required by the SEM Listing Rules, the Information Note relating to the issue of the new shares, will be made available for inspection for at least 10 business days, during normal office hours (from 9 a.m. to 5 p.m. Mauritian time) at the registered office of the Company at 6th Floor, Tower A, 1 Cybercity, Ebene, Republic of Mauritius, as from 14 October 2024. The Information Note will also be available on the Company's website: <https://www.africurepharma.com/>.

This announcement is not an invitation to the public to subscribe for shares in the Company and is provided for information purposes only.

By order of the Board

14 October 2024

For further information please contact:

SEM Authorised Representative & Sponsor



+230 402 0890

Company Secretary



+230 403 6000

This notice is issued pursuant to SEM Listing Rule 11.3. The Board of Africure accepts full responsibility for the accuracy of the information contained in this announcement.